Use of biologic therapy in racial minorities with rheumatoid arthritis from 2 US health care systems

Gail S. Kerr, Christopher Swearingen, Ted R Mikuls, Yusuf Yazici

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: In the United States, there is racial/ethnic disparity in the care of rheumatoid arthritis (RA), yet there are limited data regarding the impact of varied health care systems on treatment outcomes. Objective: The aim fo this study was to compare the frequencies of use of disease-modifying antirheumatic drugs and biologic agents in racialminorities with RA in a single-payer and variable-access health systems. Methods: Rheumatoid arthritis disease status was examined in the Ethnic Minority Rheumatoid Arthritis Consortium (EMRAC) and Veterans Affairs Rheumatoid Arthritis Registry (VARA); frequencies of prednisone and disease-modifying antirheumatic drugs and biologic agent use at enrollment were documented. Comparisons in frequencies of RA therapies between RA cohorts and white and nonwhite racial subsets were evaluated. Results: The combined cohorts provided 2899 subjects for analysis (EMRAC = 943, VARA = 1956). Routine Assessment of Patient Index Data 3 and Disease Activity Score in 28 Joints scores were equivalent (cohort, racial subsets), as was biologic agent use (26% vs. 28%) between whites and nonwhites. Disease-modifying antirheumatic drug use was greater in EMRAC nonwhites compared with their white counterparts, but similar to all VARA patients (33% vs. 22% [P < 0.001], 36%, 39%, respectively). However, biologic agent use was significantly greater in EMRAC versus VARA patients (37% vs. 22%, P < 0.001). In VARA patients, there was no difference in biologic agent use among racial subsets (22% vs. 21%). In EMRAC patients, biologic agent use was greater in whites than in nonwhites (EMRAC white 45% vs. EMRAC nonwhite 33%, P < 0.001; odds ratio, 1.66) and compared with all VARA subjects (EMRAC white 45% vs. all VARA 22%, P < 0.001; odds ratio, 2.91). Younger age, advanced education, longstanding disease, and severe disease were associated with biologic agent use. Conclusions: When compared with more variable-access systems, a VA system of care that includes a single-payer insurancemay afford equality in use of biologic agents among different racial subsets.

Original languageEnglish (US)
Pages (from-to)12-18
Number of pages7
JournalJournal of Clinical Rheumatology
Volume23
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Biological Therapy
Rheumatoid Arthritis
Delivery of Health Care
Biological Factors
Veterans
Registries
Antirheumatic Agents
Odds Ratio

Keywords

  • Biologic therapy
  • Racial disparity
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Use of biologic therapy in racial minorities with rheumatoid arthritis from 2 US health care systems. / Kerr, Gail S.; Swearingen, Christopher; Mikuls, Ted R; Yazici, Yusuf.

In: Journal of Clinical Rheumatology, Vol. 23, No. 1, 01.01.2017, p. 12-18.

Research output: Contribution to journalArticle

Kerr, Gail S. ; Swearingen, Christopher ; Mikuls, Ted R ; Yazici, Yusuf. / Use of biologic therapy in racial minorities with rheumatoid arthritis from 2 US health care systems. In: Journal of Clinical Rheumatology. 2017 ; Vol. 23, No. 1. pp. 12-18.
@article{3f1aa5ee475e4526b6ff5e98b4070dda,
title = "Use of biologic therapy in racial minorities with rheumatoid arthritis from 2 US health care systems",
abstract = "Background: In the United States, there is racial/ethnic disparity in the care of rheumatoid arthritis (RA), yet there are limited data regarding the impact of varied health care systems on treatment outcomes. Objective: The aim fo this study was to compare the frequencies of use of disease-modifying antirheumatic drugs and biologic agents in racialminorities with RA in a single-payer and variable-access health systems. Methods: Rheumatoid arthritis disease status was examined in the Ethnic Minority Rheumatoid Arthritis Consortium (EMRAC) and Veterans Affairs Rheumatoid Arthritis Registry (VARA); frequencies of prednisone and disease-modifying antirheumatic drugs and biologic agent use at enrollment were documented. Comparisons in frequencies of RA therapies between RA cohorts and white and nonwhite racial subsets were evaluated. Results: The combined cohorts provided 2899 subjects for analysis (EMRAC = 943, VARA = 1956). Routine Assessment of Patient Index Data 3 and Disease Activity Score in 28 Joints scores were equivalent (cohort, racial subsets), as was biologic agent use (26{\%} vs. 28{\%}) between whites and nonwhites. Disease-modifying antirheumatic drug use was greater in EMRAC nonwhites compared with their white counterparts, but similar to all VARA patients (33{\%} vs. 22{\%} [P < 0.001], 36{\%}, 39{\%}, respectively). However, biologic agent use was significantly greater in EMRAC versus VARA patients (37{\%} vs. 22{\%}, P < 0.001). In VARA patients, there was no difference in biologic agent use among racial subsets (22{\%} vs. 21{\%}). In EMRAC patients, biologic agent use was greater in whites than in nonwhites (EMRAC white 45{\%} vs. EMRAC nonwhite 33{\%}, P < 0.001; odds ratio, 1.66) and compared with all VARA subjects (EMRAC white 45{\%} vs. all VARA 22{\%}, P < 0.001; odds ratio, 2.91). Younger age, advanced education, longstanding disease, and severe disease were associated with biologic agent use. Conclusions: When compared with more variable-access systems, a VA system of care that includes a single-payer insurancemay afford equality in use of biologic agents among different racial subsets.",
keywords = "Biologic therapy, Racial disparity, Rheumatoid arthritis",
author = "Kerr, {Gail S.} and Christopher Swearingen and Mikuls, {Ted R} and Yusuf Yazici",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/RHU.0000000000000472",
language = "English (US)",
volume = "23",
pages = "12--18",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Use of biologic therapy in racial minorities with rheumatoid arthritis from 2 US health care systems

AU - Kerr, Gail S.

AU - Swearingen, Christopher

AU - Mikuls, Ted R

AU - Yazici, Yusuf

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: In the United States, there is racial/ethnic disparity in the care of rheumatoid arthritis (RA), yet there are limited data regarding the impact of varied health care systems on treatment outcomes. Objective: The aim fo this study was to compare the frequencies of use of disease-modifying antirheumatic drugs and biologic agents in racialminorities with RA in a single-payer and variable-access health systems. Methods: Rheumatoid arthritis disease status was examined in the Ethnic Minority Rheumatoid Arthritis Consortium (EMRAC) and Veterans Affairs Rheumatoid Arthritis Registry (VARA); frequencies of prednisone and disease-modifying antirheumatic drugs and biologic agent use at enrollment were documented. Comparisons in frequencies of RA therapies between RA cohorts and white and nonwhite racial subsets were evaluated. Results: The combined cohorts provided 2899 subjects for analysis (EMRAC = 943, VARA = 1956). Routine Assessment of Patient Index Data 3 and Disease Activity Score in 28 Joints scores were equivalent (cohort, racial subsets), as was biologic agent use (26% vs. 28%) between whites and nonwhites. Disease-modifying antirheumatic drug use was greater in EMRAC nonwhites compared with their white counterparts, but similar to all VARA patients (33% vs. 22% [P < 0.001], 36%, 39%, respectively). However, biologic agent use was significantly greater in EMRAC versus VARA patients (37% vs. 22%, P < 0.001). In VARA patients, there was no difference in biologic agent use among racial subsets (22% vs. 21%). In EMRAC patients, biologic agent use was greater in whites than in nonwhites (EMRAC white 45% vs. EMRAC nonwhite 33%, P < 0.001; odds ratio, 1.66) and compared with all VARA subjects (EMRAC white 45% vs. all VARA 22%, P < 0.001; odds ratio, 2.91). Younger age, advanced education, longstanding disease, and severe disease were associated with biologic agent use. Conclusions: When compared with more variable-access systems, a VA system of care that includes a single-payer insurancemay afford equality in use of biologic agents among different racial subsets.

AB - Background: In the United States, there is racial/ethnic disparity in the care of rheumatoid arthritis (RA), yet there are limited data regarding the impact of varied health care systems on treatment outcomes. Objective: The aim fo this study was to compare the frequencies of use of disease-modifying antirheumatic drugs and biologic agents in racialminorities with RA in a single-payer and variable-access health systems. Methods: Rheumatoid arthritis disease status was examined in the Ethnic Minority Rheumatoid Arthritis Consortium (EMRAC) and Veterans Affairs Rheumatoid Arthritis Registry (VARA); frequencies of prednisone and disease-modifying antirheumatic drugs and biologic agent use at enrollment were documented. Comparisons in frequencies of RA therapies between RA cohorts and white and nonwhite racial subsets were evaluated. Results: The combined cohorts provided 2899 subjects for analysis (EMRAC = 943, VARA = 1956). Routine Assessment of Patient Index Data 3 and Disease Activity Score in 28 Joints scores were equivalent (cohort, racial subsets), as was biologic agent use (26% vs. 28%) between whites and nonwhites. Disease-modifying antirheumatic drug use was greater in EMRAC nonwhites compared with their white counterparts, but similar to all VARA patients (33% vs. 22% [P < 0.001], 36%, 39%, respectively). However, biologic agent use was significantly greater in EMRAC versus VARA patients (37% vs. 22%, P < 0.001). In VARA patients, there was no difference in biologic agent use among racial subsets (22% vs. 21%). In EMRAC patients, biologic agent use was greater in whites than in nonwhites (EMRAC white 45% vs. EMRAC nonwhite 33%, P < 0.001; odds ratio, 1.66) and compared with all VARA subjects (EMRAC white 45% vs. all VARA 22%, P < 0.001; odds ratio, 2.91). Younger age, advanced education, longstanding disease, and severe disease were associated with biologic agent use. Conclusions: When compared with more variable-access systems, a VA system of care that includes a single-payer insurancemay afford equality in use of biologic agents among different racial subsets.

KW - Biologic therapy

KW - Racial disparity

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85007304614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007304614&partnerID=8YFLogxK

U2 - 10.1097/RHU.0000000000000472

DO - 10.1097/RHU.0000000000000472

M3 - Article

VL - 23

SP - 12

EP - 18

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 1

ER -